Dr Annalisa Jenkins
Chair of the Board of Directors
Annalisa Jenkins, MBBS, FRCP, joined the Board of Directors as Chairperson in December 2017. Prior to joining Cell Medica, Dr. Jenkins served as President and CEO of Dimension Therapeutics and held multiple leadership positions, including Executive Vice President, Head of Global Research and Development for Merck Serono, where she led global medical affairs and quality and was a member the Pharmaceutical Executive Committee. Prior to this, Dr. Jenkins had a successful 14-year career at Bristol-Myers Squibb (BMS), attaining the role of Senior Vice President and Head of Global Medical Affairs. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital, University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service. Dr. Jenkins is a board member of several growing companies and a member of the Science Board to the U.S. Food & Drug Administration (FDA). She also serves on the board of the Center for Talent Innovation in the U.K.
Dr Thomas Hecht
Thomas has been on the Cell Medica Board since 2012 and he was Chairman until December 2017. He was previously Vice President Marketing at Amgen Europe, Lucerne, Switzerland. Following his academic career, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he served as Co-Head of the Program for Bone Marrow Transplantation, University of Freiburg, Germany.
Today, he provides services to the pharmaceutical industry in clinical development/ marketing and licensing strategies.
He also serves as Chairman of Affimed NV, Vaximm AG and Aelix Therapeutics SA. In 2009, with the acquisition by Alcon, he stepped down as Chairman of ESBATech AG; and in 2015, with the acquisition by Baxter International Inc., from his post as Chairman of the Supervisory Council of SuppreMol GmbH.
Thomas earned his MD at the University of Freiburg.
Dr Nigel Burns
Nigel has extensive experience in product and company management and has held a series of leadership roles, one of which was Senior Vice President at Cambridge Antibody Technology. Nigel has also held a number of Board level positions in companies such as Glythera and currently at Cell Medica. Additionally, he was formerly non-executive Director of Navion, Director and Founder of Nascient and, most recently, CEO and Founder of SweetSpot Therapeutics Ltd. Furthermore, he was an entrepreneur-in-residence for Imperial Innovations and has served on multiple national and international scientific and industry advisory boards and committees.
Nigel has a PhD in biophysics from King’s College, London and a BSc in biochemistry from Imperial College London.
Dr Allan Marchington
Allan Marchington is an experienced investor with a strong track record of success. In 2006 Allan and his Partners founded Apposite Capital, an international healthcare investment company based in London. While at Apposite, Allan has served on the Board of a number of companies including Calchan Ltd., Birdrock Bio Inc., Ambrx Inc., Ambit Biosciences Inc., Convergence Pharmaceuticals Ltd, and Sotera Wireless. Prior to establishing Apposite, Allan worked in a number of senior roles, including Entrepreneur in Residence, Abingworth Management and Senior Vice President, Millennium Pharmaceuticals Inc. based in Cambridge Mass. Prior to Millennium, Allan was principal founder and CEO of Cambridge Combinatorial, a combinatorial chemistry company which was successfully sold to Millennium in 2000. Allan has a PhD in Chemistry from the University of Liverpool and after leaving University, worked for seven years in a range of therapeutic areas at Pfizer.
Founder and CEO
After a successful, 22-year-long career in investment banking based in London and New York, Gregg completed his MSc degree in immunology at Imperial College School of Medicine, London.
Recognizing the significant progress taking place in the field of cellular immunotherapy, Gregg formed Cell Medica in collaboration with a small group of leading clinicians and immunologists who were pioneering this new type of medical treatment.
Gregg holds an MSc in immunology from Imperial College School of Medicine in London, as well as an MBA from the University of Chicago and a BA in biochemistry from Harvard University.